Evidence map›Paper›PMID 33438175›Full record

SynthesisJournal of cancer survivorship : research and practice2023

Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review.

Hannah C Timmins, David Mizrahi, Tiffany Li, Matthew C Kiernan, David Goldstein, Susanna B Park

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of cancer survivorship : research and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Summary of evidence on comprehensive healthcare for chemotherapy-induced peripheral neuropathy in cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hannah C TimminsBrain and Mind Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0001-5504-1625
David MizrahiPrince of Wales Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, Australia.
Tiffany LiBrain and Mind Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Matthew C KiernanBrain and Mind Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
David GoldsteinPrince of Wales Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, Australia.
Susanna B ParkBrain and Mind Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia. susanna.park@sydney.edu.au.

Funding

Cancer Institute NSW 14/TPG/1-05National Health and Medical Research Council 1080521National Health and Medical Research Council 1132524National Health and Medical Research Council 1148595National Health and Medical Research Council 1156093
6 · The paper itself

Abstract

purposeChemotherapy-induced peripheral neurotoxicity (CIPN) is a common dose-limiting toxicity of cancer treatment causing functional impairment and impacting quality of life. Effective prevention and treatment of CIPN are lacking, and CIPN risk factors remain ill-defined. Metabolic syndrome and associated conditions have emerged as potential risk factors, due to their high prevalence and independent association with nerve dysfunction. This systematic review aimed to investigate the association between these common metabolic-lifestyle factors and CIPN.

methodsSearches were undertaken using Medline, Embase, CINAHL, Scopus, and Web of Science databases, with additional studies identified from bibliographic references cited by original and review articles. Articles that analyzed metabolic-lifestyle risk factors associated with CIPN for patients treated with platinum- or taxane-based chemotherapy were included.

resultsSearches identified 6897 titles; 44 articles had full text review, with 26 studies included. Overall incidence of neuropathy ranged from 16.9 to 89.4%. Obesity had the most consistent patient-oriented evidence as a risk factor for CIPN, with moderate evidence suggesting diabetes did not increase CIPN incidence or severity. A limited number of studies supported an association with low physical activity and greater CIPN risk.

conclusionsComorbidities and lifestyle factors, particularly obesity and low physical activity, may contribute to the development of CIPN. The implementation of sensitive outcome measures in large-scale clinical trials is required to further elucidate CIPN risk factors and evaluate if changes in lifestyle would improve long-term CIPN outcomes for cancer survivors. IMPLICATIONS FOR CANCER SURVIVORS: Better understanding of CIPN risk profiles may inform personalized medicine strategies and help elucidate pathophysiological mechanisms which could be targeted for neuroprotection.

Indexed as

Antineoplastic AgentsCancer SurvivorsNeurotoxicity SyndromesPeripheral Nervous System DiseasesBridged-Ring CompoundsHumansLife StyleObesityPlatinumQuality of LifeRisk FactorsTaxoidsAntineoplastic AgentsBridged-Ring CompoundsPlatinumtaxaneTaxoidsChemotherapyDiabetesNeuropathyObesityPhysical activityRisk factors

Identifiers

PMID33438175

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.